Navigation Links
Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
Date:5/16/2008

Results of international, multi-center registry presented at conference

NATICK, Mass., May 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that results from an international, multi-center patient registry documenting the safety and clinical utility of the SpyGlass(R) Direct Visualization System will be presented at Digestive Disease Week(R) (DDW), which runs from May 17-22 in San Diego, CA. Registry results will be announced in three separate scientific oral presentations scheduled for Tuesday, May 20. In addition, a total of 15 abstracts on the clinical utility of the SpyGlass System will be presented at the conference, underscoring its widespread acceptance in physician practices.

The SpyGlass patient registry reports on clinical data from 296 patients at 15 U.S. and European medical centers who required peroral cholangioscopy (PO) for the treatment or diagnosis of biliary stones or indeterminate strictures with suspected pathology.

The SpyGlass System is the first single-use direct visualization system that requires only a single physician operator and provides four-way steerability in a four lumen single-use catheter. The catheter provides two dedicated irrigation channels in addition to a 1.2 mm working channel through which diagnostic and therapeutic devices can be used in the biliary ducts. The system includes a miniature 6,000-pixel fiber optic probe attached to a camera that provides physicians with a direct view of a patient's bile ducts, overcoming some of the visual challenges of conventional endoscopic retrograde cholangiography (ERC) procedures.

"We are excited that DDW provides an opportunity to highlight the safety and therapeutic benefits of the SpyGlass Syst
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
2. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
3. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
4. Fraunhofer and Boston University Hosted Prestigious SME Tour
5. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
6. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
7. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
8. Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
9. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
10. Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology
11. Boston Scientific Announces Japanese Approval of Heart Failure Lead
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... Nov. 2, 2011 Cadence Pharmaceuticals, Inc. (NASDAQ: ... developing and commercializing proprietary products principally for use in ... and CEO Ted Schroeder will present the company,s corporate ... Time (3:30pm Eastern Time) during the Credit Suisse Healthcare ...
... 2011 Quanterix Corporation, a company enabling a ... its revolutionary Si ngle Mo lecule ... analytical performance of its Prostate Specific Antigen (PSA) ... improvement in sensitivity over today,s ultrasensitive third-generation PSA ...
... In preparation for its European launch ... 50 years, Human Genome Sciences (HGS) needed a customer ... European commercial sales team. The company had a long ... mobility, industry-specific functionality, speed, and low system maintenance. Veeva ...
Cached Biology Technology:Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 3
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... degrees Celsius. But not salt water: Due to ... is below zero. And sea water tends to freeze ... so-called "brine channels," are formed in the ice. The ... remain in a liquid state even at lower temperatures, and ...
... satellite data, a team of scientists led by researchers from ... created a model that can successfully predict the severity and ... the rest of South America months in advance. ... the primary factor that drives the distribution of fires in ...
... rely on animals for pollination, the number of seeds they ... and the successful deposition of pollen. The number of visits ... well as on conspecific plant density. But what if a ... or has very few pollinators visiting its flowers? Will all ...
Cached Biology News:CO2 bonds in sea ice: Small living creatures with major impact 2Ocean temperatures can predict Amazon fire season severity 2Ocean temperatures can predict Amazon fire season severity 3How does a plant survive with few mates or pollinators? A European herb has figured out its own way 2How does a plant survive with few mates or pollinators? A European herb has figured out its own way 3